Press release
Cytomegalovirus (CMV) Infection Market Set to Witness Significant Growth by 2025-2034
Cytomegalovirus (CMV) Infection Market
Cytomegalovirus (CMV) is a common herpesvirus infection that affects people of all ages. While usually asymptomatic in healthy individuals, CMV can cause severe complications in newborns (congenital CMV) and immunocompromised patients, including organ transplant recipients, cancer patients, and individuals with HIV/AIDS. Congenital CMV is one of the leading causes of birth defects and developmental disabilities globally.
The market for CMV treatment and prevention is gaining momentum due to the rising burden of congenital CMV infections, growing transplant procedures, and expanding research into antivirals, monoclonal antibodies, and vaccine candidates.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71736
Market Overview
The global Cytomegalovirus (CMV) Infection market was valued at USD 700 million in 2024 and is projected to reach USD 1.6 billion by 2034, growing at a CAGR of 8.7% during the forecast period.
Key Highlights
• Market Size 2024: Estimated at USD 700 million
• Forecast 2034: Expected to reach USD 1.6 billion
• CAGR (2025-2034): 8.7%
Market Drivers
• Rising incidence of congenital CMV and complications in immunocompromised patients.
• Increasing number of organ transplants requiring CMV prophylaxis and treatment.
• Advances in antiviral drug development with better safety and efficacy.
• Expanding pipeline of CMV vaccines and monoclonal antibodies.
Market Challenges
• Limited awareness and screening programs for congenital CMV.
• High toxicity and side effects of existing antiviral drugs (e.g., ganciclovir).
• Lack of standardized guidelines for universal CMV screening.
Leading Players
Key companies in the CMV market include Roche, Merck & Co., Takeda Pharmaceutical Company Limited, Atara Biotherapeutics, Chimerix Inc., Moderna, Novartis AG, Gilead Sciences, Bristol Myers Squibb, and Johnson & Johnson.
Segmentation Analysis
By Product
• Antiviral Drugs (Ganciclovir, Valganciclovir, Letermovir, Foscarnet, Cidofovir)
• Monoclonal Antibodies
• Vaccine Candidates (Pipeline)
• Adjunctive Therapies
By Technology
• Oral Therapy
• Injectable Therapy
• Cell-Based / Immunotherapy Approaches
By End Use
• Hospitals
• Specialty Clinics
• Research Institutes
• Homecare Settings
By Application
• Congenital CMV
• Transplant-Associated CMV
• Immunocompromised Patients (HIV, Cancer)
• Others
Summary:
The market is currently dominated by antivirals, particularly valganciclovir and letermovir, while the future lies in monoclonal antibodies and vaccines targeting prevention. Congenital CMV represents the largest unmet need, driving R&D and awareness initiatives.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71736/cytomegalovirus-cmv-infection-market
Regional Analysis
• North America
Largest market, supported by advanced healthcare infrastructure, strong transplant programs, and ongoing CMV vaccine trials in the U.S.
• Europe
Holds a significant share, driven by national congenital CMV awareness campaigns and adoption of new antivirals across Germany, France, and the UK.
• Asia-Pacific
Expected to post the fastest growth due to high birth rates, increasing transplant surgeries, and expanding pharmaceutical research in China, India, and Japan.
• Middle East & Africa
Smaller market but growing gradually with improving healthcare systems and pediatric infection management programs.
• Latin America
Emerging market, particularly in Brazil and Mexico, where congenital CMV is gaining recognition as a public health challenge.
Regional Summary:
North America and Europe dominate current revenues, while Asia-Pacific is projected to post the highest CAGR, supported by demographic trends and rising healthcare investments.
Market Dynamics
Key Growth Drivers
• Rising congenital CMV cases fueling demand for screening and preventive care.
• Increasing use of antivirals in organ transplant patients.
• Growing pipeline of CMV vaccine candidates in clinical trials.
• Expanding patient advocacy and government-backed awareness programs.
Key Challenges
• High toxicity of current antivirals limiting long-term use.
• Lack of standardized global screening protocols.
• Low awareness among pregnant women and healthcare providers.
Latest Market Trends
• FDA approval of letermovir (Prevymis) for transplant-related CMV prophylaxis.
• Advancements in mRNA-based CMV vaccines (e.g., Moderna candidates).
• Development of monoclonal antibodies offering targeted CMV prevention.
• Integration of digital tools and AI-driven screening methods to enhance early detection.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71736
Competitor Analysis
Major Players
• Roche - Leading with antiviral portfolios for immunocompromised patients.
• Merck & Co. - Developer of letermovir (Prevymis), a breakthrough CMV prophylaxis drug.
• Takeda Pharmaceutical Company Limited - Expanding rare disease and antiviral pipeline.
• Atara Biotherapeutics - Focused on cell-based immunotherapies for CMV.
• Chimerix Inc. - Advancing antiviral research for resistant infections.
• Moderna - Developing mRNA-based CMV vaccines.
• Novartis AG - Broad antiviral research programs.
• Gilead Sciences - Known for expertise in antiviral drug development.
• Bristol Myers Squibb & Johnson & Johnson - Diversifying into viral infection therapies.
Competitive Landscape Summary:
The CMV market is evolving from reliance on toxic antivirals toward safer, targeted antivirals, monoclonal antibodies, and vaccines. Companies like Merck and Moderna are leading innovation, while biotechs and big pharma form partnerships to accelerate product pipelines.
Conclusion
The Cytomegalovirus (CMV) Infection market is projected to grow from USD 700 million in 2024 to USD 1.6 billion by 2034, at a CAGR of 8.7%. Growth is fueled by rising awareness of congenital CMV, expanding transplant populations, and advances in antivirals, monoclonal antibodies, and vaccines.
While challenges remain - particularly toxicity of existing drugs and limited global screening - the outlook is optimistic as governments, NGOs, and pharmaceutical companies prioritize CMV prevention and treatment.
Outlook:
North America and Europe will remain the largest revenue contributors, while Asia-Pacific will post the strongest growth, driven by demographics, rising transplants, and healthcare investments. Companies that develop safe, effective, and widely accessible preventive and therapeutic options will define the future of the CMV market.
This report is also available in the following languages : Japanese (サイトメガロウイルス(CMV)感染症市場), Korean (거대세포바이러스(CMV) 감염 시장), Chinese (巨细胞病毒(CMV)感染市场), French (Marché des infections à cytomégalovirus (CMV)), German (Markt für Cytomegalovirus-Infektionen (CMV)), and Italian (Mercato delle infezioni da citomegalovirus (CMV)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71736
Our More Reports:
Oncology Biosimilars Market
https://exactitudeconsultancy.com/reports/72359/oncology-biosimilars-market
Non Invasive Fat Reduction Market
https://exactitudeconsultancy.com/reports/72360/non-invasive-fat-reduction-market
CDK4 / 6 Inhibitors Market
https://exactitudeconsultancy.com/reports/72361/cdk4-6-inhibitors-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus (CMV) Infection Market Set to Witness Significant Growth by 2025-2034 here
News-ID: 4177761 • Views: …
More Releases from Exactitude Consultancy
Hepatitis D (HDV) Market to Reach USD 1.1 Billion by 2034
Hepatitis D virus (HDV), also known as delta hepatitis, is a rare but severe form of viral hepatitis that occurs only in individuals infected with the hepatitis B virus (HBV). HDV coinfection or superinfection significantly accelerates liver disease progression, leading to cirrhosis, liver failure, and hepatocellular carcinoma.
Despite affecting an estimated 12-15 million people worldwide, HDV remains underdiagnosed and under-treated. Historically, treatment options were limited to interferon therapies with modest efficacy.…
Epstein-Barr Virus (EBV) Market Growth, Applications, Innovations and Business O …
Introduction
The Epstein-Barr Virus (EBV), a member of the herpesvirus family, is one of the most common human viruses. It infects over 90% of the global population, often during childhood or adolescence, and remains dormant in the body for life. EBV is best known as the cause of infectious mononucleosis ("mono"), but it has also been linked to more serious conditions, including Hodgkin's lymphoma, Burkitt's lymphoma, gastric cancer, nasopharyngeal carcinoma, and…
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Mark …
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Outlook 2024-2034: Rising Antimicrobial Resistance Spurs Innovation in Antibiotics and Diagnostics
Introduction
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are among the most severe healthcare-associated infections (HAIs), typically occurring in critically ill patients or those requiring prolonged mechanical ventilation. These infections are associated with high morbidity, mortality, and healthcare costs, making them a central focus for antimicrobial stewardship and drug development.
HABP and VABP…
Interstitial Cystitis Market is projected to reach USD 4.3 billion by 2034
Interstitial Cystitis (IC), also known as bladder pain syndrome (BPS), is a chronic urological condition characterized by pelvic pain, urinary urgency, and increased frequency without evidence of bacterial infection. Affecting millions worldwide, IC has a significant impact on quality of life and remains difficult to diagnose and manage due to its complex pathophysiology.
Current therapies primarily focus on symptom relief, including oral drugs, intravesical treatments, bladder instillations, and lifestyle modifications. However,…
More Releases for CMV
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus (CMV) Vaccine Market | Exploring Current Trends and Growth Statu …
Cytomegalovirus (CMV) Vaccine Market Outlook and Investment Analysis
What is the current outlook for the Cytomegalovirus (CMV) vaccine market?
The CMV vaccine market is seeing positive growth due to the increasing prevalence of CMV infections globally, particularly in immunocompromised populations such as organ transplant recipients and HIV patients. Moreover, the growing awareness of CMV's impact on newborns has contributed to the push for preventive vaccines. A few vaccines are in advanced clinical…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
Global Commercial Cooking Device Market Forecast 2018-2025 CMV Sharper Finish, Q …
Market study on Global Commercial Cooking Device 2018 Research Report presents a professional and complete analysis of Global Commercial Cooking Device Market on the current market situation.
Report provides a general overview of the Commercial Cooking Device industry 2018 including definitions, classifications, Commercial Cooking Device market analysis, a wide range of applications and Commercial Cooking Device industry chain structure. The 2018's report on Commercial Cooking Device industry offers the global…
Cytomegalovirus (CMV) Market: Size, Status, Opportunity Analysis and Forecasts t …
A new independent 162 page research with title 'Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe or Asia and important players/vendors such as Atara Bio, Biotest AG, Helocyte, Merck & Co., Novartis, Shire, ViraCyte With n-number of tables and figures examining the Cytomegalovirus (CMV) Market, the research gives…
Cytomegalovirus (CMV) Infection Treatment and Diagnosis Market Opportunity Analy …
Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that remain dormant in the human body. CMV infection can occur in people of all ages worldwide. CMV is a communicable disease that spreads through body fluids such as saliva, blood, urine, semen, and breast milk. Presence of CMV infection can be detected by various testing methods based on which the global cytomegalovirus infection treatment and diagnosis market can…
